Biliary Tract Cancers: Is Laparoscopic Liver Resection Adequate?

2022 Year in Review - Cholangiocarcinoma —January 5, 2023

Categories:

Cholangiocarcinoma

The safety and adequacy of laparoscopic liver surgery has not been well established in biliary tract cancers. An institutional retrospective matched cohort study identified patients in the Mayo Clinic’s institutional database who underwent laparoscopic versus open surgery and compared clinical operative and postoperative variables. Results from this study were shared at the 2022 International Hepato-Pancreato-Biliary Association World Congress.

A total of 87 patients were identified; 33 underwent laparoscopic surgery and 54 underwent open resection. The patients who underwent laparoscopic resections had significantly less blood loss, higher negative-margin resection rates, shorter length of stay, and lower number of harvested lymph nodes, and these patients were less likely to have major liver resection. There were no between-group differences in procedural time, tumor size, severe postoperative complications, need for adjuvant chemotherapy, or need for readmission.

The researchers concluded that “laparoscopic liver resections for GBC and iCCA are safe and appear to have at least some short-term benefits with appropriate patient selection and when these procedures are done by a high volume, experienced center. They also do not compromise any of the oncologic outcomes.”

Flavio Rocha, MD, FACS, FSSP, Physician-in-Chief of the Knight Cancer Institute, noted that these results were hypothesis-generating: “I do think the shorter operative procedures can certainly help patients get onto adjuvant therapy quicker, which we know ultimately is what they need to control micrometastatic disease after surgery.”

Source: Pery R, Starlinger P, Fiorentini G, et al. Laparoscopic versus open liver resections for gallbladder cancer and intrahepatic cholangiocarcinoma: the Mayo Clinic experience. International Hepato-Pancreato-Biliary Association World Congress 2022. Abstract FP10-5.

Related Articles
First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)
Special Issues and Supplements
Use of first-line (1L) IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin (gem-cis) chemotherapy in patients with locally advanced or metastatic biliary tract cancers
Key Advances in the Treatment of Patients with BTC in 2023: New Targeted Therapies, Potential Biomarkers, and Combination Strategies
2023 Year in Review - Cholangiocarcinoma
In 2023, much research has been conducted on the treatment of biliary tract cancer (BTC), with an emphasis on novel targeted therapies and combination strategies. Important advances in treatment for patients with BTC were presented at society conferences such as the American Society of Clinical Oncology (ASCO), ASCO GI, and European Society for Medical Oncology.
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review - Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country